News & Updates
Filter by Specialty:
Antiseizure effect of cannabidiol seen within 2 weeks of treatment
In the treatment of patients with drug-resistant epilepsy associated with tuberous sclerosis complex, the antiseizure effect of cannabidiol occurs within 6–10 days, according to the results of a phase III trial. Adverse events also emerge during the first 2 weeks of the titration period, and majority of these are resolved during the 16-week treatment period.
Antiseizure effect of cannabidiol seen within 2 weeks of treatment
28 Mar 2022
IV steroids may do more harm than good in older-onset ulcerative colitis
In patients with older-onset ulcerative colitis (UC), treatment with intravenous (IV) steroids appears to be less effective and is associated with higher risks of surgery and adverse events relative to patients with younger-onset disease, a study has found.
IV steroids may do more harm than good in older-onset ulcerative colitis
26 Mar 2022
TYK2 inhibitor for psoriatic arthritis clears phase II trial
In the treatment of patients with psoriatic arthritis, the use of the selective TYK2 inhibitor deucravacitinib appears to be effective and well tolerated, leading to greater improvements in American College of Rheumatology (ACR) domains, enthesitis endpoints, and multiple patient-reported, psoriasis-related outcomes relative to placebo, as shown in the results of a phase II trial.
TYK2 inhibitor for psoriatic arthritis clears phase II trial
26 Mar 2022
TNFi use does not induce hypertension in ankylosing spondylitis
Use of tumour necrosis factor inhibitor (TNFi) does not appear to contribute to incident hypertension in individuals with ankylosing spondylitis (AS), reports a study.
TNFi use does not induce hypertension in ankylosing spondylitis
25 Mar 2022
Apalutamide for castration-resistant prostate cancer yields real-world results
Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have been initiated on apalutamide in a real-world setting appear to show prostate-specific antigen (PSA) response that is strong and consistent with that reported in clinical trials, as reported in a study.
Apalutamide for castration-resistant prostate cancer yields real-world results
25 Mar 2022
Sotrovimab reduces hospitalization, death in patients with COVID-19 regardless of serostatus
Treatment with sotrovimab reduces the risk of all-cause hospitalization or death in patients with COVID-19 who are at high risk of progression to severe disease, regardless of anti-SARS-CoV-2 serostatus, according to a study presented at CROI 2022.
Sotrovimab reduces hospitalization, death in patients with COVID-19 regardless of serostatus
23 Mar 2022
Novel EGFR-TKI drug shows favourable antitumour activity in NSCLC
Treatment with the novel EGFR tyrosine kinase inhibitors (EGFR-TKI) abivertinib at 300 mg twice a day appears to be effective in patients with EGFR T790M-positive nonsmall cell lung cancer (NSCLC), while having manageable side effects, according to the results of a phase II trial.
Novel EGFR-TKI drug shows favourable antitumour activity in NSCLC
22 Mar 2022
Age, medication use affect initial response to SARS-CoV-2 vaccines among IBD patients
Most patients with inflammatory bowel disease (IBD) build an initial immune response to SARS-CoV-2 vaccination, but older patients, those treated with antitumour necrosis factor (anti-TNF) and an immunomodulator, and those on corticosteroids may require an additional vaccine dose to achieve better immunity against COVID-19, according to a study.